Gene ther­a­py 3.0 ef­forts net Sali­o­Gen a nine-fig­ure Se­ries B, but much re­mains un­der wraps

Rough­ly 10 months ago, a fledg­ling biotech emerged from stealth with a mod­est Se­ries A and a big promise look­ing to de­vel­op gene ther­a­py 3.0. The promise inched clos­er to re­al­i­ty Wednes­day as in­vestors have now hopped on board thanks to a new, nine-fig­ure round.

Sali­o­Gen Ther­a­peu­tics closed its $115 mil­lion Se­ries B, the com­pa­ny an­nounced Wednes­day morn­ing, aim­ing to push for­ward its “gene cod­ing” plat­form and grow­ing pre­clin­i­cal pipeline. The biotech, which fo­cus­es on ac­ti­vat­ing dor­mant mam­malian en­zymes to ed­it genes in vi­vo, se­cured the new raise af­ter flesh­ing out some of the tech­nolo­gies’ ap­pli­ca­tions, CEO Ray Tabib­i­azar told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER